JPMorgan Downgrades Editas Medicine, Says Focus Shift Sparks Investor Caution

Editas Medicine Inc. (NASDAQ:EDIT) announced last week a strategic realignment to focus on in vivo gene editing.

The shift is designed to optimize costs, extend its cash runway into the second quarter of 2027, and accelerate its progress toward achieving human proof of concept within two years.

Also Read: Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts

JPMorgan spoke with Editas management. The analyst said that, overall, they were surprised by the timing of the restructuring. While there are personnel and legal considerations, the pivot would be better received if delivered in a single step, the analyst wrote.

JPMorgan highlighted the strategic move to …

Full story available on Benzinga.com